Shares of Nvidia (NVDA) have gained 1.2% over the past four weeks to close the last trading session at $187.24, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $256 indicates a potential upside of 36.7%.The mean estimate comprises 45 short-term price targets with a standard deviation of $42.86. While the lowest estimate of $140.00 indicates a 25.2% decline from the current price ...

Fulcrum Therapeutics, Inc. (FULC) closed the last trading session at $11.99, gaining 21.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19 indicates a 58.5% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $6.89. While the lowest estimate of $7.00 indicates a 41.6% decline from the current price level, the most optimistic a ...

Core Viewpoint - Biohaven Ltd. (BHVN) shares have increased by 11.6% over the past four weeks, closing at $10.5, with a mean price target of $19.8 indicating a potential upside of 88.6% according to Wall Street analysts [1] Price Targets - The average of 15 short-term price targets ranges from a low of $9.00 to a high of $50.00, with a standard deviation of $12.49, indicating variability among analysts [2] - The lowest estimate suggests a decline of 14.3% from the current price, while the highest estimate indicates a potential upside of 376.2% [2] Analyst Sentiment - Analysts show a consensus that BHVN will report better earnings than previously estimated, which supports the potential for stock price increases [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 4%, with one estimate moving higher and no negative revisions [12] Zacks Rank - BHVN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to concerns about analysts' biases and the accuracy of their estimates [3][10] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can be a starting point for further research [9]

Core Viewpoint - The Beachbody Company, Inc. (BODI) has shown significant stock price appreciation of 82.1% over the past four weeks, with a mean price target of $11.5 suggesting a further upside potential of 30.2% [1] Price Targets and Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $4.45, indicating variability among analysts. The lowest estimate is $6.50 (26.4% decline), while the highest is $15.50 (75.5% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7][10] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - There is growing optimism among analysts regarding BODI's earnings prospects, supported by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 64.9%, with two estimates moving higher and no negative revisions [12] - BODI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of BODI's potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Customers Bancorp (CUBI) has seen a 1.6% increase in share price over the past four weeks, closing at $65, with analysts suggesting a potential upside of 30.4% based on a mean price target of $84.75 [1][11]. Price Targets - The average price target consists of eight estimates ranging from a low of $68.00 to a high of $95.00, with a standard deviation of $9.5, indicating variability among analysts [2]. - The lowest estimate suggests a 4.6% increase from the current price, while the highest indicates a 46.2% upside [2]. Analyst Sentiment - Analysts show strong agreement regarding CUBI's ability to report better earnings than previously predicted, which supports the expectation of a stock price increase [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 7.4%, with four estimates moving higher and no negative revisions [12]. Zacks Rank - CUBI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Price Movement Implications - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14].

Core Viewpoint - Masimo (MASI) shows potential for upside based on Wall Street analysts' short-term price targets, with a mean target of $186.14 indicating a 26.6% upside from the current price of $147.03 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $14.16, suggesting variability among analysts; the lowest estimate is $168.00 (14.3% increase), while the highest is $210.00 (42.8% increase) [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates - Analysts have shown increasing optimism about MASI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 3.5% over the past month, with three estimates increasing and no negative revisions [12] Zacks Rank - MASI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of MASI's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Nektar Therapeutics (NKTR) shares have shown a 1.4% increase over the past month, closing at $57.67, with analysts suggesting a potential upside of 62.8% based on a mean price target of $93.86 [1][11]. Price Targets and Analyst Consensus - The average price target for NKTR is derived from seven short-term estimates, ranging from a low of $30.00 to a high of $120.00, with a standard deviation of $29.13, indicating variability in analyst predictions [2]. - The lowest estimate suggests a potential decline of 48%, while the highest indicates an upside of 108.1% [2]. - A smaller standard deviation reflects greater agreement among analysts regarding price movement, which can be a useful starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about NKTR's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.7%, with two estimates moving higher and no negative revisions [12]. - NKTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in predicting actual stock price movements [3][7]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8][10].

Core Viewpoint - Ambac Financial Group (AMBC) shares have increased by 19.4% in the past four weeks, closing at $9.91, with a mean price target of $14.67 indicating a potential upside of 48% [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.51, where the lowest estimate is $10.00 (0.9% increase) and the highest is $19.00 (91.7% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement [2][9] Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, one estimate has increased, leading to a 3.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - AMBC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of potential gains, but the implied direction of price movement is a useful guide [14]

Core Viewpoint - Veritone, Inc. (VERI) has seen a 21.7% increase in share price over the past four weeks, closing at $6.39, with analysts suggesting a potential upside of 65.9% based on a mean price target of $10.6 [1][11]. Price Targets - The average price target for VERI ranges from a low of $3.00 to a high of $25.00, with a standard deviation of $8.5, indicating significant variability among analyst estimates [2]. - The lowest estimate suggests a decline of 53.1% from the current price, while the highest estimate indicates a potential upside of 291.2% [2]. Analyst Consensus - There is strong agreement among analysts regarding VERI's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 1.4% over the past month, with no negative revisions, indicating positive sentiment [12]. Zacks Rank - VERI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13]. Caution on Price Targets - While price targets are a common metric for investors, relying solely on them can be misleading, as analysts may set overly optimistic targets due to business incentives [3][8][10].

Core Viewpoint - Liquidia Corporation (LQDA) has seen a 9.7% increase in share price over the past four weeks, closing at $26.42, with a potential upside of 62.3% based on Wall Street analysts' mean price target of $42.89 [1] Price Targets - The average price target consists of nine estimates ranging from a low of $6.00 to a high of $67.00, with a standard deviation of $16.92, indicating variability among analysts [2] - The lowest estimate suggests a decline of 77.3%, while the highest indicates a potential upside of 153.6% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][9] Analyst Sentiment - Analysts have shown increasing optimism about LQDA's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - Over the last 30 days, four earnings estimates have been revised upward, leading to a 45.4% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a useful indication of the expected direction of price movement [14]